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Summary
Background: Beef tapeworm (Taenia saginata) infection is acquired by eating inadequately
cooked beef that contains the larvae or cysticerci of T. saginata. Niclosamide and praziquantel
have proved effective for its treatment but treatment failures are well known. We report herein
the results of nitazoxanide therapy.
Methods: A prospective study was conducted in 18 children and 34 adults to assess the efficacy
and safety of nitazoxanide in the treatment of niclosamide- and praziquantel-resistant T.
saginata infection. Nitazoxanide was administered twice daily for 3 days in 500-mg doses for
those aged over 14 years and at 20 mg/kg body weight/day in children aged 5—14 years. Post-
treatment follow-up was undertaken at 1, 2, 4, 8, and 12 weeks for fecal samples for proglottides,
and to check the presence, number, and viability of Taenia eggs.
Results: Nitazoxanide cured 51 of 52 (98.1%) patients. Mild side effects occurred in seven
patients, which resolved spontaneously. There were no abnormalities in laboratory parameters.
Conclusions: Nitazoxanide is a safe, effective, inexpensive, and well-tolerated drug for the
treatment of niclosamide- and praziquantel-resistant beef tapeworm infection.
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Beef tapeworm (Taenia saginata) infection is acquired by
eating inadequately cooked beef that contains the larvae or* Corresponding author. Tel.: +91 194 2312092;
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doi:10.1016/j.ijid.2007.04.017cysticerci of T. saginata. It is found worldwide and about 45
million suffer from this disease. Its greatest economic
impact, however, is within tropical and sub-tropical cattle
rearing countries: Africa, the Middle East, Central and South
America, Europe, and Asia.
Although many antimicrobial drugs are used to treat T.
saginata infections, niclosamide and praziquantel have
proved effective for its treatment; however treatmentPublished by Elsevier Ltd. All rights reserved.
Treatment of beef tapeworm infection with nitazoxanide 81failures are well known.1—4 In Kashmir, India, with a 95%
Muslim population and absence of pigs, T. saginata is ende-
mic but Taenia solium infection is almost unknown. We
report herein the results of nitazoxanide therapy in 52
patients, identified in a population-based epidemiological
survey, infected with T. saginata resistant to multiple
courses of niclosamide, praziquantel, or both.
Materials and methods
Between 2004 and 2005, an epidemiological survey for tae-
niasis was conducted in Sonawari tehsil in the district of
Baramulla, Kashmir, India involving 8894 persons from semi-
urban and urban villages. During this survey 55 persons with
confirmed T. saginata infection resistant to multiple courses
of niclosamide or praziquantel or both were identified. Three
patients were excluded because one was pregnant and two
were lactating. The remaining 52 gave written informed
consent to participate in the study. There were 18 children,
24 men, and 10 women. They ranged in age from 5 to 65
years, with a mean of 26.2  16.1 years. The duration of
infection ranged from 8 months to 15 years with a mean of
3.7  3.1 years. All patients had received two to seven
courses (median three) of niclosamide and 10 had received
one to three courses of praziquantel (median two) but had
continued to pass proglottides with stools. All had demon-
strated a relapse 3—6 weeks after initiation of treatment.
Symptoms included passage of proglottides in stools and/or
trousers while bending, running or washing (n = 52),
increased appetite (n = 33), abdominal discomfort (n = 23),
nausea (n = 15), and diarrhea (n = 3). Nitazoxanide was admi-
nistered twice daily for 3 days in 500-mg doses for those aged
over 14 years and 20 mg/kg body weight/day in children aged
5—14 years without prior fasting or laxative use.
All patients underwent physical examination including ana-
lysis of hemogram, serum chemistry (liver function tests,
glucose, urea, sodium and potassium), and urine, and electro-
cardiogram before and 7 days after treatment. Stool speci-
menswerecollected for routineexamination. Egg viabilitywas
tested by staining with methylene blue, and egg count by
Stoll’s method. Patients were followed at 1, 2, 4, 8, and 12
weeks for the passage of proglottides, and fecal samples were
examined for the presence, number, and viability of Taenia
eggs. Overall 51 of 52 patients (98.1%) responded and passed
worms ranging from 1 to 6 meters in length, but no worm
contained scolex. All responders stopped passing proglottides
at amedian of 3 days (range 1—5) days. Of the 41 patients who
provided stool specimens in the first week, 38 (92.7%) had
negative stool examinations for proglottides and eggs. The
reduction was in excess of 98% in egg count and from amedian
of 100% to 0% in viability at 1 week. Subsequent stool exam-
inations at 2, 4, 8, and 12weekswere negative for proglottides
and eggs with a cure rate of 98.1% (51 of 52 patients).
Thirty-two patients (15 children and 17 adolescents and
adults) were positive for another parasite in stool at study
enrollment. These included Ascaris lumbricoides (n = 19),
Trichuris trichiura (n = 6), Giardia lamblia (n = 4), and mixed
infections (n = 3). Nitazoxanide cured 89.5% (17/19), 100%
(6/6), 75% (3/4), and 66.7% (2/3) of the cases of ascariasis,
trichuriasis, giardiasis, and mixed infections, respectively.
Eleven adverse events occurred in seven patients including
diarrhea (n = 3), mild abdominal pain (n = 3), headache(n = 2), nausea (n = 2), and giddiness (n = 1). All adverse
events were mild and transitory in nature and resolved
spontaneously without discontinuation of treatment. No
abnormality was observed in hemogram, blood chemistry
values, or urine analysis.
Discussion
The present study demonstrated that a 3-day course of
nitazoxanide cured 98.1% of patients infected with T. sagi-
nata unresponsive to niclosamide, praziquantel, or both.
Nitazoxanide was safe and well tolerated. Adverse events
reported by patients were mild and resolved easily without
any treatment. In two previous clinical studies in patients
infected with T. saginata, nitazoxanide cured 21 of 22
patients (95.5%) and five of five patients (100%).5,6 Taenia
saginata infections are endemic in Kashmir, India. Niclosa-
mide or praziquantel are safe and effective drugs for its
treatment but therapeutic failures with these drugs are
encountered.
Taeniasis is not only a significant public health problem but
also an important economic problem in endemic areas. It is
becoming increasingly clear that it should be given greater
priority because of its economic impact, particularly in
resource-poor countries. Most patients are asymptomatic
and become aware of the infection when they notice proglot-
tides or segments of tapeworm in stools or motile proglot-
tides emerging from the anus, in trousers, on bedding, while
bending, walking, and running, and this can cause huge
psychological distress. Rarely, migration of motile proglot-
tides or worm to ectopic sites such as the appendix, biliary
tree, or pancreatic duct can cause morbidity.
Nitazoxanide (2-acetyloxy-N-(5-nitro-2-thiazolyl)benza-
mide) is a new thiazolide antiparasitic agent that shows
excellent activity against a wide variety of protozoa and
helminths. Although developed in 1980, the literature on
its use is scanty because it only received approval by the US
FDA in November 2002 for the treatment of diarrhea caused
by Cryptosporidium parvum and Giardia lamblia in children
and adults. It became available in India in June 2004. It is also
effective against a broad range of other parasitic infections
including Hymenolepis nana, Trichuris trichiura, Ascaris lum-
bricoides, Fasciola hepatica, Entamoeba histolytica, and
Taenia solium/saginata.7
In conclusion nitazoxanide is a safe, effective, and inex-
pensive drug for the treatment of niclosamide- and prazi-
quantel-resistant T. saginata infections. It represents a
significant addition to the antiparasitic arsenal in the treat-
ment of intestinal parasitic infections.
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